Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CLDX

Celldex Therapeutics Inc

May 08 • 04:00PM ET

33.97

+0.65 1.95 %

Healthcare • Biotechnology • USA • Mid • NASD

May 07, 6:18 PMCelldex posts Q1 2026 results with non-GAAP EPS $-1.18 and revenue $15,000, missing EPS and revenue estimates

Peers: IOVA XNCR IMCR TGTX FATE

| Held by: VTI IWM XBI VXF IWN SCHA VTWO DFAS VHT DFMC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.27	Insider Own	2.86%	Shs Outstand	78.46M	Perf Week	5.14%
Market Cap	2.67B	Forward P/E	-	EPS next Y	-4.40	Insider Trans	-2.33%	Shs Float	76.22M	Perf Month	1.04%
Enterprise Value	2.22B	PEG	-	EPS next Q	-1.05	Inst Own	93.19%	Short Float	10.90%	Perf Quarter	42.97%
Income	-283.65M	P/S	3064.80	EPS this Y	-11.48%	Inst Trans	4.07%	Short Ratio	8.09	Perf Half Y	43.15%
Sales	0.87M	P/B	4.96	EPS next Y	-1.23%	ROA	-45.36%	Short Interest	8.31M	Perf YTD	25.07%
Book/sh	6.85	P/C	5.97	EPS next 5Y	6.26%	ROE	-48.94%	52W High	35.79 -5.09%	Perf Year	74.03%
Cash/sh	5.69	P/FCF	-	EPS past 3/5Y	-17.59% -14.07%	ROIC	-62.11%	52W Low	18.00 88.72%	Perf 3Y	1.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-13.13% -26.93%	Gross Margin	-288.80%	Volatility	4.79% 3.95%	Perf 5Y	24.39%
Dividend TTM	-	EV/Sales	2553.48	EPS Y/Y TTM	-58.13%	Oper. Margin	-35688.45%	ATR (14)	1.49	Perf 10Y	-35.11%
Dividend Ex-Date	-	Quick Ratio	8.92	Sales Y/Y TTM	-88.54%	Profit Margin	-32753.58%	RSI (14)	56.83	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	8.92	EPS Q/Q	-45.87%	SMA20	1.34%	Beta	0.98	Target Price	57.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-97.84%	SMA50	6.77%	Rel Volume	0.77	Prev Close	33.32
Employees	198	LT Debt/Eq	0.00	Earnings	May 07 AMC	SMA200	26.60%	Avg Volume	1.03M	Price	33.97
IPO	May 15, 1986	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.59% -98.11%	Trades		Volume	794,141	Change	1.95%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-20-26	Upgrade	Barclays	Underweight → Overweight	$45
Mar-23-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$44
Oct-21-25	Initiated	Mizuho	Outperform	$48
Oct-13-25	Initiated	Barclays	Underweight	$25
Apr-28-25	Initiated	Canaccord Genuity	Buy	$64
Mar-20-25	Initiated	Morgan Stanley	Overweight	$46
Feb-13-25	Initiated	UBS	Buy	$44
Oct-07-24	Initiated	Citigroup	Buy	$70
Sep-30-24	Initiated	Goldman	Neutral	$45
Sep-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-18-24	Initiated	Stifel	Buy	$58
Jun-11-24	Initiated	Wolfe Research	Outperform	$51
Dec-20-23	Initiated	TD Cowen	Outperform
Nov-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$27
Aug-22-23	Initiated	Wells Fargo	Underweight	$21
Sep-17-21	Initiated	Jefferies	Buy	$66
Sep-10-21	Initiated	SVB Leerink	Outperform	$68
Jul-22-21	Initiated	Guggenheim	Buy	$66
Feb-21-20	Initiated	Cantor Fitzgerald	Overweight	$8
Aug-01-17	Resumed	H.C. Wainwright	Buy	$10

Show Previous Ratings

May-07-26 04:37PM	Celldex: Q1 Earnings Snapshot (Associated Press)
04:01PM	Celldex Reports First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-13-26 04:01PM	Celldex to Present at Upcoming Investor Conference (GlobeNewswire)
Apr-06-26 10:53AM	Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Apr-02-26 12:26PM	Celldex shares plunge after dumping $300 million stock deal (GuruFocus.com)
09:48PM	Loading…
Apr-01-26 09:48PM	Celldex Announces Pricing of $300 Million Public Offering of Common Stock (GlobeNewswire)
04:01PM	Celldex Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-27-26 10:30AM	Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 (GlobeNewswire)
Mar-08-26 11:46AM	Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference (MarketBeat)
Mar-01-26 09:45AM	Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 (GlobeNewswire)
Feb-28-26 01:26PM	Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory (Insider Monkey)
Feb-27-26 02:45PM	Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 (GlobeNewswire)
Feb-26-26 01:52PM	Celldex Therapeutics Stock Earns 88 RS Rating (Investor's Business Daily)
Feb-25-26 04:37PM	Celldex: Q4 Earnings Snapshot (Associated Press Finance) +24.07%
04:01PM	Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
07:01AM	Loading…
07:01AM	Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Feb-23-26 08:01AM	Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile (GlobeNewswire) +5.65%
Feb-12-26 01:38AM	Celldex Therapeutics Teases Key Barzolvolimab Phase 3 Updates, New Data at Guggenheim Summit (MarketBeat)
Feb-11-26 12:01AM	Top Picks 2026- Celldex Therapeutics Inc. CLDX (MoneyShow)
Feb-09-26 08:01AM	Celldex to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-27-26 04:02PM	2 Strong Buy Growth Stocks With Upside of Around 200% (Barchart) -5.57%
Dec-22-25 03:46PM	Celldex Therapeutics Stock Gets RS Rating Lift (Investor's Business Daily) +6.52%
Dec-21-25 09:57AM	Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 (Insider Monkey)
Dec-09-25 08:01AM	Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism (GlobeNewswire) -5.74%
Nov-10-25 04:34PM	Celldex: Q3 Earnings Snapshot (Associated Press Finance) +7.50%
04:01PM	Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
08:01AM	Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer (GlobeNewswire)
Nov-07-25 08:01AM	Celldex to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-06-25 08:00AM	Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20 (GlobeNewswire)
08:00AM	Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study (GlobeNewswire)
04:01PM	Loading…
Oct-30-25 04:01PM	Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition (GlobeNewswire)
Oct-20-25 11:08PM	Barclays Initiates Coverage of Celldex Therapeutics (CLDX) With an Underweight Rating (Insider Monkey)
Oct-13-25 05:52AM	Barclays initiates coverage on U.S. small & mid-cap biotech stocks (Investing.com)
Oct-10-25 09:40AM	Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? (Zacks)
Sep-17-25 05:11AM	Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 (GlobeNewswire)
Sep-09-25 09:01AM	Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-22-25 06:27AM	FDA cancels adcomm on Biohaven drug; Catalent lays off staff (BioPharma Dive)
Aug-20-25 12:13AM	LifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PT (Insider Monkey) -13.03%
Aug-19-25 04:01PM	Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) (GlobeNewswire)
Aug-07-25 05:55PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:50PM	Celldex: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-25 05:31PM	KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 \| DelveInsight (PR Newswire)
Jul-25-25 08:13AM	scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock? (Zacks)
Jun-24-25 01:01AM	CLDX- A Promising Biotech Name Targeting CSU (MoneyShow) +6.18%
Jun-14-25 10:48AM	Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 (GlobeNewswire)
Jun-12-25 06:01PM	Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 (GlobeNewswire)
Jun-11-25 11:30AM	Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-10-25 04:01PM	Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress (GlobeNewswire)
Jun-06-25 08:01AM	Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors (GlobeNewswire) +9.32%
May-09-25 10:34AM	Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey) -6.10%
May-08-25 05:10PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:14PM	Celldex: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-25 04:01PM	Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease (GlobeNewswire) -9.31%
Apr-22-25 07:40AM	Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (Seeking Alpha)
Mar-24-25 03:24PM	Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? (Zacks) +5.80%
Mar-20-25 11:44AM	Celldex a new overweight at Morgan Stanley on urticaria candidate (SeekingAlpha)
Mar-04-25 08:01AM	Celldex Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-03-25 08:01AM	Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 (GlobeNewswire) -5.93%
Mar-01-25 12:45PM	Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 (GlobeNewswire)
Feb-27-25 05:30PM	Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:32PM	Celldex: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Dec-19-24 08:01AM	Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis (GlobeNewswire)
Nov-20-24 08:01AM	Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases (GlobeNewswire) +5.68%
Nov-11-24 04:01PM	Celldex Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 05:30PM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.65%
04:25PM	Celldex: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-24 12:05PM	Celldex selloff creates buying opportunity, says Guggenheim (TipRanks)
Oct-26-24 05:43PM	Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria (GlobeNewswire)
Oct-25-24 08:01AM	Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 (GlobeNewswire)
Oct-23-24 08:39AM	Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results (Insider Monkey)
Oct-15-24 06:10PM	Celldex Therapeutics, Inc. (CLDX): Hedge Funds Hidden Gem in Small-Cap Stocks (Insider Monkey)
Sep-25-24 10:45AM	Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 (GlobeNewswire) -12.06%
Sep-16-24 08:01AM	Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 (GlobeNewswire)
Sep-14-24 05:18PM	Celldex Therapeutics, Inc. (CLDX): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-12-24 04:01PM	Celldex Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.77%
Aug-08-24 05:25PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Celldex: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-29-24 04:01PM	Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria (GlobeNewswire) -5.77% -8.45%
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-16-24 08:01AM	Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria (GlobeNewswire)
Jun-11-24 07:00PM	Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ... (GuruFocus.com)
Jun-04-24 04:01PM	Celldex Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
Jun-02-24 09:01AM	Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 (GlobeNewswire)
May-27-24 09:55AM	Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet (Zacks)
May-15-24 11:33AM	Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study (MT Newswires)
08:01AM	Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis (GlobeNewswire)
May-09-24 09:55AM	Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade (Zacks)
May-06-24 09:55PM	CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:22PM	Celldex: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-17-24 08:01AM	Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria (GlobeNewswire)
Apr-09-24 09:35AM	Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) (Zacks)
Apr-08-24 12:00PM	All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy (Zacks)
09:35AM	Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX) (Zacks)
Mar-20-24 09:55AM	Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect? (Zacks)

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Martin Samuel Bates	SVP AND CFO	Jan 02 '26	Option Exercise	10.38	4,817	50,000	32,942	Jan 06 04:23 PM
PEPIN RONALD	SR. VP & CBO	Dec 15 '25	Option Exercise	5.47	19,333	105,714	20,097	Dec 17 04:06 PM
Jimenez Freddy A.	SVP & GENERAL COUNSEL	Dec 04 '25	Sale	29.09	4,166	121,210	30,796	Dec 08 04:20 PM
FREDDY A JIMENEZ	Officer	Dec 04 '25	Proposed Sale	29.10	4,166	121,210		Dec 04 04:04 PM
Wright Richard M.	Former Officer	Nov 13 '25	Option Exercise	14.06	49,298	692,913	70,131	Nov 17 04:17 PM
Wright Richard M.	Former Officer	Nov 13 '25	Sale	24.00	49,298	1,183,177	20,833	Nov 17 04:17 PM
RICHARD M WRIGHT	Officer	Nov 13 '25	Proposed Sale	24.00	49,298	1,183,177		Nov 13 04:15 PM
Jimenez Freddy A.	SVP & GENERAL COUNSEL	Aug 13 '25	Sale	24.77	771	19,096	34,962	Aug 15 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLDX

Celldex Therapeutics Inc

Upgrade your Finviz experience